Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma

Expert Opinion on Biological Therapy

Volumn 13, Issue SUPPL.1, 2013, Pages

  Amodio, Nicola ^a   Di Martino, Maria Teresa ^a   Neri, Antonino ^b   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

MicroRNA; MiRNA; MiRNA therapeutics; Multiple myeloma; Non coding RNA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA DIRECTED RNA POLYMERASE III; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; INTERLEUKIN 6; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 15A; MICRORNA 16; MICRORNA 181A; MICRORNA 181B; MICRORNA 192; MICRORNA 194; MICRORNA 19A; MICRORNA 19B; MICRORNA 203; MICRORNA 21; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 29B; PIWI INTERACTING RNA; PIWI PROTEIN; POLYCOMB GROUP PROTEIN; RNA POLYMERASE II; SMALL NUCLEOLAR RIBONUCLEOPROTEIN; SMALL NUCLEOLAR RNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

3' UNTRANSLATED REGION; BONE MARROW CELL; CHROMOSOME 13; EPIGENETICS; GENE CLUSTER; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; LYMPHATIC LEUKEMIA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PATHOGENESIS; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; MULTIPLE MYELOMA; PROGNOSIS; RNA, UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL;

EID: 84879592480     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.796356     Document Type: Review

References (100)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
2. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26:595-608
3. Tassone P, Tagliaferri P, Rossi M, et al. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer 2006;42:1530-8
4. Morabito F, Recchia AG, Mazzone C, et al. Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium. Curr Cancer Drug Targets 2012;12:743-56
5. Calimeri T, Battista E, Conforti F, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11
6. Tassone P, Neri P, Burger R, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012;12:814-22
7. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-16
8. Tassone P, Neri P, Kutok JL, et al. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood 2005;106:1341-5
9. Tassone P, Tagliaferri P, Rossi M, et al. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 2009;9:854-70
10. Tassone P, Tagliaferri P, Fulciniti MT, et al. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. Curr Pharm Des 2007;13:487-96
11. Ditzel Santos D, Ho AW, Tournilhac O, et al. Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007;35:1366-75
12. Rossi M, Di Martino MT, Morelli E, et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:757-67
13. Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 2007;13:5903-9
14. Tassone P, Galea E, Forciniti S, et al. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 2002;21:867-73
15. Tassone P, Forciniti S, Galea E, et al. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone. Cell Death Differ 2000;7:327-8
16. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1- oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004;64:4629-36
17. Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011;118:6368-79
18. Neri P, Ren L, Azab AK, et al. Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011;117:6202-13
19. Neri P, Tagliaferri P, Di Martino MT, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008;143:520-31
20. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89
21. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet 2009;10:155-9
22. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011;12:861-74
23. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97
24. Ying SY, Lin SL. Current perspectives in intronic micro RNAs (miRNAs). J Biomed Sci 2006;13:5-15
25. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004;432:231-5
26. Eulalio A, Huntzinger E, Nishihara T, et al. Deadenylation is a widespread effect of miRNA regulation. RNA 2009;15:21-32
27. Aravin AA, Hannon GJ, Brennecke J. The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science 2007;318:761-4
28. Klattenhoff C, Theurkauf W. Biogenesis and germline functions of piRNAs. Development 2008;135:3-9
29. Gunawardane LS, Saito K, Nishida KM, et al. A slicer-mediated mechanism for repeat-associated siRNA 5' end formation in Drosophila. Science 2007;315:1587-90
30. Pal-Bhadra M, Leibovitch BA, Gandhi SG, et al. Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 2004;303:669-72
31. Sasaki T, Shiohama A, Minoshima S, et al. Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics 2003;82:323-30
32. Horwich MD, Li C, Matranga C, et al. The Drosophila RNA methyltransferase, DmHen1, modifies germline piRNAs and single-stranded siRNAs in RISC. Curr Biol 2007;17:1265-72
33. Carmell MA, Girard A, van de Kant HJ, et al. MIWI2 is essential for spermatogenesis and repression of transposons in the mouse male germline. Dev Cell 2007;12:503-14
34. King TH, Liu B, McCully RR, et al. Ribosome structure and activity are altered in cells lacking snoRNPs that form pseudouridines in the peptidyl transferase center. Mol Cell 2003;11:425-35
35. Ni J, Tien AL, Fournier MJ. Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA. Cell 1997;89:565-73
36. Pagano A, Castelnuovo M, Tortelli F, et al. New small nuclear RNA gene-like transcriptional units as sources of regulatory transcripts. PLoS Genet 2007;3:e1
37. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009;458:223-7
38. Bejerano G, Lowe CB, Ahituv N, et al. A distal enhancer and an ultraconserved exon are derived from a novel retroposon. Nature 2006;441:87-90
39. Calin GA, Liu CG, Ferracin M, et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007;12:215-29
40. Kapranov P, Cheng J, Dike S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007;316:1484-8
41. Seila AC, Calabrese JM, Levine SS, et al. Divergent transcription from active promoters. Science 2008;322:1849-51
42. Taft RJ, Glazov EA, Cloonan N, et al. Tiny RNAs associated with transcription start sites in animals. Nat Genet 2009;41:572-8
43. Feuerhahn S, Iglesias N, Panza A, et al. TERRA biogenesis, turnover and implications for function. FEBS Lett 2010;584:3812-18
44. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12
45. Lionetti M, Agnelli L, Lombardi L, et al. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012;12:823-37
46. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004
47. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885-90
48. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101:11755-60
49. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008;111:5078-85
50. Tassone P, Tagliaferri P. Editorial: new approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 2012;12:741-2
51. Tagliaferri P, Rossi M, Di Martino MT, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838-46
52. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009;114:e20-6
53. Zhang Y, Roccaro AM, Rombaoa C, et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012;120:1678-86
54. Agnelli L, Mosca L, Fabris S, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009;48:603-14
55. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010;24:629-37
56. Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010;107:7904-9
57. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
58. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009;113:6669-80
59. Corthals SL, Jongen-Lavrencic M, de Knegt Y, et al. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010;34:677-81
60. Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011;52:1787-94
61. Amodio N, Di Martino MT, Foresta U, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012;3:e436
62. Wang X, Li C, Ju S, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011;52:1991-8
63. Melo SA, Moutinho C, Ropero S, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010;18:303-15
64. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 2009;325:965
65. Sarasquete ME, Gutierrez NC, Misiewicz-Krzeminska I, et al. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2011;96:468-71
66. Bonci D. MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent pat Cardiovasc Drug Discov 2010;5:156-61
67. Lionetti M, Agnelli L, Mosca L, et al. Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 2009;48:521-31
68. Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 2007;104:3300-5
69. de Larrea CF, Navarro A, Tejero R, et al. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation. Clin Cancer Res 2012;18:3697-704
70. Ohler U, Yekta S, Lim LP, et al. Patterns of flanking sequence conservation and a characteristic upstream motif for microRNA gene identification. RNA 2004;10:1309-22
71. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70
72. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18:367-81
73. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, et al. Restoration of miR-214 expression reduces growth of myeloma cells through a positive regulation of P53 and inhibition of DNA replication. Haematologica 2013;98(4):640-8
74. Chen L, Li C, Zhang R, et al. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011;309:62-70
75. Fulciniti M, Amin S, Nanjappa P, et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011;17:6500-9
76. Rossi M, Pitari MRAmodio N, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 2012; Epub ahead of print
77. Wong KY, Yim RL, So CC, et al. Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011;118:5901-4
78. Wong KY, Liang R, So CC, et al. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 2011;154:569-78
79. Amodio N, Leotta M, Bellizzi D, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012;3:1246-58
80. Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer 2012;12:84-8
81. Lopez-Corral L, Mateos MV, Corchete LA, et al. Genomic analysis of high-risk smoldering multiple myeloma. Haematologica 2012;97:1439-43
82. Chu L, Su MY, Maggi LB Jr, et al. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest 2012;122:2793-806
83. Ronchetti D, Todoerti K, Tuana G, et al. The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer J 2012;2:e96
84. Michel CI, Holley CL, Scruggs BS, et al. Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metabol 2011;14:33-44
85. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007;129:1311-23
86. Keller S, Sanderson MP, Stoeck A, et al. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006;107:102-8
87. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80:193-208
88. Huang JJ, Yu J, Li JY, et al. Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol 2012;29:2402-8
89. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107:1987-96
90. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 2011;6:1130-46
91. Lal A, Navarro F, Maher CA, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 2009;35:610-25
92. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010;29:1580-7
93. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30
94. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-22
95. Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137:1005-17
96. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003;21:74-81
97. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-9
98. Leone E, Morelli E, Di Martino MT, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013;8):2096-106
99. Di Martino MT, Gulla A, Cantafio ME, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55
100. Obad S, dos Santos CO, Petri A, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011;43:371-8